BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024: H.C. Wainwright 26th Annual Global Investment ConferenceCorporate PresentationMonday, September 9, 2024, at 7:00 a.m. ET. Virtual and New York, NY 2024 Cantor Fitzgerald Global Healthcare ...

临床试验进展 - 公司目前有4个在研产品候选药物处于早期开发阶段[87,88] - SNS-101一期/二期临床试验的剂量递增部分已完成,数据显示该药物单药及联合用药安全性良好,无剂量限制毒性[87] - SNS-101联合用药组出现1例部分缓解反应,3例肿瘤缩小反应[87] - 公司计划扩大SNS-101临床试验,额外纳入50-70例患者,以优化二期试验设计[89] - 公司预计将于2024年底前报告剂量扩展队列的初步数据,并与FDA进行一期试验终点会议[88] 财务状况 - 公司预计现有现金及等价物将支持运营开支和资本支出需求至2025年第四季度[89] - 公司可能需要通过股权发行、债务融资、合作、战略联盟以及营销、分销或许可安排等方式筹集额外资金,以满足未来的资金需求[122,123,124] 研发费用 - 研发费用同比下降200,000美元,主要由于外部研究费用减少700,000美元、临床试验费用减少300,000美元、咨询费用减少200,000美元和设施费用减少100,000美元,部分被临床试验费用增加900,000美元和人员成本增加200,000美元所抵消[103] 管理费用 - 管理费用同比下降2,190,000美元,主要由于与2023年股东大会相关的外部专业服务费用减少1,600,000美元、人员成本(包括股票激励)减少400,000美元和董事和高管保险费用减少200,000美元[104] 其他收益 - 其他收益同比减少146,000美元,主要是由于利息收入减少200,000美元,部分被2023年处置设备产生的损失100,000美元所抵消[105] 会计政策 - 公司在2023年12月31日的年度报告中披露了关键会计政策,在2024年6月30日结束的六个月内没有重大变化[126] - 公司将采用新的会计准则,预计不会对财务报表产生重大影响[127] 公司定位 - 公司符合"新兴成长公司"的定义,可以享受相关的披露豁免政策,直到公司不再符合该定义[128,129,130] - 公司也被定义为"较小报告公司",可以享受相关的披露豁免政策[131,132] - 作为较小报告公司,公司无需提供市场风险的定量和定性披露[133]

财务状况 - 公司在2024年第二季度的现金、现金等价物和有价证券总额为5230万美元，预计可以支持运营到2025年第四季度[8] - 公司有信心利用现有现金为运营提供资金支持到2025年第四季度[8] 研发进展 - 公司在2024年5月在ASCO年会上发布了SNS-101的临床数据，显示了良好的临床活性和安全性[5] - 公司正在推进SNS-101临床试验的剂量扩展阶段，计划在2024年底前公布初步数据并与FDA进行1期临床试验终点会议[6] - 公司在2024年4月在《自然通讯》杂志上发表了SNS-101作用机制的同行评议研究论文[6] - 公司的SNS-102、SNS-103和SNS-201等其他候选药物正在开发中[11,12] 费用管控 - 公司在2024年第二季度的研发费用为458.4万美元，较2023年同期下降[9] - 公司在2024年第二季度的一般及行政费用为320.3万美元，较2023年同期下降[10] - 公司在2024年第二季度的净亏损为714.2万美元，较2023年同期下降[10] 管理团队 - 公司任命Josiah Craver为公司高级副总裁兼财务总监[7]

- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial re ...

- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial re ...

Sensei Biotherapeutics (NASDAQ:SNSE) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors. The bad news for Sensei Biotherapeutics comes from its results in this trial. The company notes that only a few patients of the 34 treated showed signs of improvement. That doesn’t seem to be sittin ...

- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the ...

- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Biotherapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 83-1863385 (State or other j ...

Exhibit 99.1 Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, MA – M ...